MRNA arrives at its August 6 earnings report with short sellers firmly positioned, options skewing to the most defensive level of the past year, and a stock down 31% in a month — a setup that frames the print as a pivotal test for a company trying to prove its mRNA platform can generate durable revenue beyond COVID vaccines.
The most acute signal heading into the report is options positioning. The put/call ratio has climbed to 1.20 — the highest reading of the past 52 weeks — running nearly two standard deviations above its 20-day average of 1.11. That level of demand for downside protection is notable on its own, but it's especially striking against the backdrop of a stock that has already shed nearly a third of its value in a single month, closing at $55.14. The PCR has drifted steadily higher since late June, when it sat below 0.90, suggesting the defensive tilt has been building rather than spiking in a single session.
Short interest reinforces the bearish lean, though the borrow market itself tells a more nuanced story. Bears hold 13.4% of the free float short — a high level that has actually declined about 13% over the past month, with shares short falling from around 61 million in early July to roughly 52 million. That partial covering coincides with the stock's sharp drop, consistent with some shorts taking profit. Borrow availability remains ample at 242%, meaning the lending pool is far from stressed — cost to borrow is a low 0.45% — so there is no near-term squeeze pressure to dislodge the remaining short base. The ORTEX short score of 67.8 keeps MRNA in elevated territory despite the recent covering.
The analyst community has been lifting targets but stopping well short of conviction. Citigroup raised its target to $60 on Monday while holding a Neutral rating. Goldman Sachs moved to $67 in late July, also staying Neutral. Morgan Stanley's $39 target and BofA's Underperform with a $38 target sit as outliers below the current price, creating a wide dispersion — the consensus mean of around $51 is itself below the stock's last close, a signal that the Street, in aggregate, sees limited upside even at these levels. Bulls point to the breadth of the mRNA pipeline — 35 candidates across oncology and cardiovascular disease — and a forward earnings growth forecast that ranks in the 83rd percentile across the universe. Bears focus on the execution record: a CMV vaccine setback, deeply negative ROA, and heavy dependence on revenue streams that have yet to materialise at scale. Capital Research added nearly 5.9 million shares through June 30, while FMR LLC remains the largest holder at 11.4% — a sign that some large institutional money has been adding, not retreating.
The August 6 print will test whether Moderna can show enough momentum in its non-COVID pipeline to justify a stock price that the majority of the Street still rates as no better than neutral, against a backdrop where options traders are more defensively positioned than at any point in the past year.
See the live data behind this article on ORTEX.
Open MRNA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
